Research programme: clotrimazole analogues - Cyclacel/Lorus

Drug Profile

Research programme: clotrimazole analogues - Cyclacel/Lorus

Alternative Names: CYC-381; NC-169; NC-219; NC-381; NC-393; NC-394; NC-407; NuChem compounds

Latest Information Update: 17 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard University
  • Developer Cyclacel Pharmaceuticals
  • Class Imidazoles
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Sep 2007 Preclinical development is ongoing
  • 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
  • 20 May 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top